Maj-Britt Kaltoft

Corporate Officer/Principal bei Statens Serum Institute

61 Jahre

Health Technology

Consumer Services

Finance

Aktive Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Sylvie Grégoire	M	62	NOVO NORDISK A/S	9 Jahre
Poul Rødbroe Rasmussen	M	-	Statens Serum Institute	-
Mette Agger	F	59	Statens Serum Institute	-
Niels Borregaard	M	73	University of Copenhagen	26 Jahre
Doug Langa	M	58	NOVO NORDISK A/S	13 Jahre
Stephen Gough	M	-	NOVO NORDISK A/S	9 Jahre

Mehr sehen

Beziehungs-Chart

Beziehungen zu mehreren Unternehmen

Ehemalige Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Christer Rosén	M	72	EffRx, Inc. EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co.	13 Jahre
Laura Spalding	F	-	EffRx, Inc. EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co.	-
Mats Gunnar Pettersson	M	78	H. LUNDBECK A/S	10 Jahre
Henrik Ramlau-Hansen	M	67	University of Copenhagen	9 Jahre
Kåre Schultz	M	62	University of Copenhagen NOVO NORDISK A/S	28 Jahre
Kim Vilbour Andersen	M	-	University of Copenhagen	5 Jahre
Jacob Tolstrup	M	52	H. LUNDBECK A/S	25 Jahre
Jacob Uittenbogaard	M	-	EffRx, Inc. EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co.	-
Nikolai Søren Kirkby	M	-	University of Copenhagen	4 Jahre
Jesper Nerlov	M	56	University of Copenhagen	8 Jahre
Lykke Friis	M	54	University of Copenhagen	10 Jahre
Ana de Jesus-Johansson	F	-	EffRx, Inc. EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co.	-
Jørn Møller Mayntzhusen	M	58	H. LUNDBECK A/S	-
Jesper Parnevik	M	-	EffRx, Inc. EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co.	13 Jahre
Lars Christian Lassen	M	-	NOVO NORDISK A/S	-
Jakob Riis	M	58	University of Copenhagen	5 Jahre
Martin Jensen	M	64	University of Copenhagen	10 Jahre
Anne Prener	M	66	NOVO NORDISK A/S	12 Jahre
Jesper Alling Coverdale Kofoed	M	-	University of Copenhagen	7 Jahre
Bratanata Perdana	M	55	Seattle University	5 Jahre
Soren Mogelsvang	M	52	University of Copenhagen	6 Jahre
Thomas Price	M	68	SANUWAVE HEALTH, INC.	1 Jahre
Peter Henrik Kürstein-Jensen	M	68	H. LUNDBECK A/S	11 Jahre
Peter Andersen	M	67	H. LUNDBECK A/S	-
Liz Hewitt	F	67	NOVO NORDISK A/S	9 Jahre
Eva Steiness	M	83	H. LUNDBECK A/S	9 Jahre
Helge Lund	M	61	NOVO NORDISK A/S	1 Jahre
Sten Scheibye	M	72	NOVO NORDISK A/S	10 Jahre
Lise Kingo	F	62	NOVO NORDISK A/S	26 Jahre
Anders Gersel Pedersen	M	73	H. LUNDBECK A/S	18 Jahre
Claus Tycho Bræstrup	M	79	H. LUNDBECK A/S	10 Jahre
Kurt Anker Nielsen	M	78	NOVO NORDISK A/S	13 Jahre
Alan Rubino	M	69	SANUWAVE HEALTH, INC.	18 Jahre
Mary Szela	F	60	NOVO NORDISK A/S	3 Jahre
Hannu Ragnvald Ryöppönen	M	72	NOVO NORDISK A/S	6 Jahre
Thomas Dywremose	M	-	University of Copenhagen	6 Jahre
Thomas Paul Koestler	M	72	NOVO NORDISK A/S	5 Jahre
Bruno Francois Jules Angelici	M	77	NOVO NORDISK A/S	6 Jahre
Jeppe Fonager Christiansen	M	64	NOVO NORDISK A/S University of Copenhagen	1 Jahre
Claus Steensen Sølje	M	52	University of Copenhagen	1 Jahre
Jacob Hübertz	M	-	University of Copenhagen	6 Jahre
Jan Fuhr Miller	M	54	H. LUNDBECK A/S	11 Jahre
Mikkel Dyhr Gadegaard	M	45	NOVO NORDISK A/S	4 Jahre
Johan Kirstein Brammer	M	48	University of Copenhagen	3 Jahre
Philip Christiani	M	-	University of Copenhagen	6 Jahre
Pamela Kirby	M	70	NOVO NORDISK A/S	3 Jahre
Christoffer Erik Lorenzen	M	48	H. LUNDBECK A/S	5 Jahre
Bradley Patricia	F	-	NOVO NORDISK A/S	2 Jahre
Lida Skifte Lennert	F	52	University of Copenhagen	-
Karen Lauberg Lauritsen	F	56	NOVO NORDISK A/S	12 Jahre
Michael Moyell Juul	M	50	University of Copenhagen	4 Jahre
Jes Trygved	M	51	H. LUNDBECK A/S	3 Jahre
Jakob Poulsen	M	-	University of Copenhagen	6 Jahre
Morten Weicher Weicher	M	-	University of Copenhagen	-
Eivind Kolding	M	64	NOVO NORDISK A/S	-
Jan Hoff	M	-	NOVO NORDISK A/S	-
Krisja Vermeylen	F	62	NOVO NORDISK A/S	3 Jahre
Christian Bornfeld	M	47	University of Copenhagen	1 Jahre
Joan Schmidt	F	60	NOVO NORDISK A/S	20 Jahre
Claus S. Kallesoe	M	-	H. LUNDBECK A/S	14 Jahre
Christian Vinding Thomsen	M	-	University of Copenhagen	3 Jahre
Mozhgan Dorkhan	M	54	NOVO NORDISK A/S	6 Jahre
Atilla Olesen	M	-	University of Copenhagen	6 Jahre
henrik Danielsen	M	-	University of Copenhagen	6 Jahre
Per Toft Valstorp	M	75	NOVO NORDISK A/S	14 Jahre
Jørgen Nergaard Gøl	M	-	University of Copenhagen	4 Jahre
Alexander U. Conrad	M	53	Seattle University	2 Jahre
Casper Bych	M	52	University of Copenhagen	3 Jahre
Martin Lauge Bek-Nielsen	M	49	University of Copenhagen	4 Jahre
Hans Henrik Munch-Jensen	M	64	H. LUNDBECK A/S	8 Jahre
John P. Slonecker	M	-	Seattle University	4 Jahre
Nils Aage Brünner	M	72	University of Copenhagen	12 Jahre
Louis Illum Honoré	M	62	University of Copenhagen	4 Jahre
Ulrik Carstens	M	-	University of Copenhagen	6 Jahre
Thomas Dyrberg	M	69	University of Copenhagen	3 Jahre
Lisbeth Hald	F	-	University of Copenhagen	4 Jahre
David Helgason	M	46	University of Copenhagen	4 Jahre
Salim Nice	M	-	Seattle University	4 Jahre
Haibin Zheng	M	-	University of Copenhagen	3 Jahre
Susanne Høiberg	M	-	University of Copenhagen	4 Jahre
Charlotte Zarp-Andersson	F	-	NOVO NORDISK A/S	-
Jørgen Wedel	M	75	NOVO NORDISK A/S	12 Jahre
Mette Carlstedt	F	56	H. LUNDBECK A/S	18 Jahre
Jørgen Okkels Nielsen	M	76	H. LUNDBECK A/S	5 Jahre
Lars Eigen Møller	M	-	University of Copenhagen	5 Jahre
Inge Holm Lauritzen	F	57	H. LUNDBECK A/S	9 Jahre
Barbara Angela Barak Rimba	F	47	Seattle University	4 Jahre
Jesper Høiland	M	63	NOVO NORDISK A/S	8 Jahre
Else Sissel Vorstrup	M	-	H. LUNDBECK A/S	-
Peter Hugreffe Ankersen	M	-	NOVO NORDISK A/S	-
Ching Hui Hsu	F	50	Seattle University	4 Jahre
Karsten Witt	M	68	University of Copenhagen	3 Jahre
Rasmus Lund	M	50	University of Copenhagen	5 Jahre
Stephen Sullivan	M	-	Seattle University	4 Jahre

Statistik

Land	Beziehungen	% des Gesamten
Dänemark	86	86,00%
Vereinigte Staaten	14	14,00%

Alter der Beziehungen

Aktive

Vergangene

Herr

Frau

Aufsichtsräte

Führungskräfte

Ursprung der Beziehungen

Börse
Insiders
Maj-Britt Kaltoft
Persönliches Netzwerk